DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Hojun | ko |
dc.contributor.author | Shin, Eui-Cheol | ko |
dc.date.accessioned | 2022-02-08T06:45:03Z | - |
dc.date.available | 2022-02-08T06:45:03Z | - |
dc.date.created | 2022-02-08 | - |
dc.date.created | 2022-02-08 | - |
dc.date.created | 2022-02-08 | - |
dc.date.issued | 2022-01 | - |
dc.identifier.citation | BMB REPORTS, v.55, no.1, pp.11 - 19 | - |
dc.identifier.issn | 1976-6696 | - |
dc.identifier.uri | http://hdl.handle.net/10203/292134 | - |
dc.description.abstract | The coronavirus disease 2019 (COVID-19) is an ongoing global pandemic caused by severe acute respiratory syndrome corona virus 2 (SARS-CoV-2). Patients with severe COVID-19 exhibit hyper-inflammatory responses characterized by excessive activation of myeloid cells, including monocytes, macrophages, and neutrophils, and a plethora of pro-inflammatory cytokines and chemokines. Accumulating evidence also indicates that hyper inflammation is a driving factor for severe progression of the disease, which has prompted the development of anti-inflammatory therapies for the treatment of patients with COVID-19. Corticosteroids, IL-6R inhibitors, and JAK inhibitors have demonstrated promising results in treating patients with severe disease. In addition, diverse forms of exosomes that exert anti-inflammatory functions have been tested experimentally for the treatment of COVID-19. Here, we briefly describe the immunological mechanisms of the hyper-inflammatory responses in patients with severe COVID-19. We also summarize current anti-inflammatory therapies for the treatment of severe COVID-19 and novel exosome-based therapeutics that are in experimental stages. | - |
dc.language | English | - |
dc.publisher | KOREAN SOCIETY BIOCHEMISTRY & MOLECULAR BIOLOGY | - |
dc.title | Hyper-inflammatory responses in COVID-19 and anti-inflammatory therapeutic approaches | - |
dc.type | Article | - |
dc.identifier.wosid | 000748563200003 | - |
dc.identifier.scopusid | 2-s2.0-85123878816 | - |
dc.type.rims | ART | - |
dc.citation.volume | 55 | - |
dc.citation.issue | 1 | - |
dc.citation.beginningpage | 11 | - |
dc.citation.endingpage | 19 | - |
dc.citation.publicationname | BMB REPORTS | - |
dc.identifier.doi | 10.5483/BMBRep.2022.55.1.152 | - |
dc.identifier.kciid | ART002807683 | - |
dc.contributor.localauthor | Shin, Eui-Cheol | - |
dc.contributor.nonIdAuthor | Choi, Hojun | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Review | - |
dc.subject.keywordAuthor | Anti-inflammation | - |
dc.subject.keywordAuthor | COVID-19 | - |
dc.subject.keywordAuthor | Exosome | - |
dc.subject.keywordAuthor | Hyper-inflam-mation | - |
dc.subject.keywordAuthor | Therapy | - |
dc.subject.keywordPlus | III INTERFERONS | - |
dc.subject.keywordPlus | EXOSOMES | - |
dc.subject.keywordPlus | DELIVERY | - |
dc.subject.keywordPlus | IDENTIFICATION | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | TOCILIZUMAB | - |
dc.subject.keywordPlus | INDUCTION | - |
dc.subject.keywordPlus | VESICLES | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.